Treatment of Acne Scars With Erbium:Yttrium Aluminum Garnet (Er:YAG) Laser Examined Under OCT

Treatment of Atrophic Facial Acne Scars With Er:YAG Laser Examined Under Optical Coherence Tomography

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03333759

Enrollment

Registered

2017-11-07

Start date

2018-08-31

Completion date

2018-12-31

Last updated

2018-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Keywords

laser, Er:YAG laser, acne, acne vulgaris, optical coherence tomography

Brief summary

This study is examining the effects of the 2940 nm Er:YAG on atrophic facial acne scars under optical coherence tomography in terms of blood flow, vessel shape, skin roughness, collagen content, and epidermal thickness.

Interventions

DEVICEAlma - Harmony XL Laser

The Erbium YAG laser at a 2940nm wavelength is used for ablative laser resurfacing as well as treating acne scars.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients should be 18-90 years of age 2. Patients should have Fitzpatrick skin types of I-III 3. Patients should have at least mild acne

Exclusion criteria

1. The patient should not be receiving any additional systemic, topical, or intralesional treatment of the scars during the study 2. Pregnant or lactating females 3. Fitzpatrick skin type of IV-VI 4. A history of keloids or hypertrophic scars 5. Scleroderma 6. Photosensitivity 7. Botulinum toxin injection, facial laser resurfacing, chemical peels, fillers, or usage of oral retinoid within the last 6 months 8. Subjects with a known history of herpes simplex

Design outcomes

Primary

Measure	Time frame	Description
Change in blood flow	During 8 weeks	Optical coherence tomography (OCT) will be used to quantitatively measure changes in facial atrophic acne scars in terms of blood flow (proportion of signals with strong dynamic signal (%)/depth (mm)).
Change in epidermal thickness	During 8 weeks	Optical coherence tomography (OCT) will be used to quantitatively measure changes in facial atrophic acne scars in terms of epidermal thickness (mm).
Change in collagen content	During 8 weeks	OCT will be used to qualitatively measure changes in facial atrophic acne scars in terms of collagen content. Collagen content will be measured in terms of brightness of OCT scan. Areas of skin that contain collagen tend to be brighter (more white in color) whereas areas with less collagen content tend to be darker.
Change in skin roughness	During 8 weeks	OCT will be used to quantitatively measure changes in facial atrophic acne scars in terms of skin roughness (µm).

Secondary

Measure	Time frame	Description
The Patient Scar Assessment Scale	During 8 weeks	Scale (1-10) used to qualitatively monitor treatment and changes in scars by the patient.
The Observer Scar Assessment Scale	During 8 weeks	Scale (1-10) used to qualitatively monitor treatment and changes in scars by the dermatologist.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026